Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAD for Post-Myocardial Infarction Heart Failure
ChiCTR2200057074Phase 4Not yet recruiting
- Sponsor
- Huadong Hospital, Fudan University
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of nicotinamide adenine dinucleotide in heart failure (HF) and myocardial infarction (MI) (2 arms), sponsored by Huadong Hospital, Fudan University. Primary endpoints: Rates of cardiovascular death and rehospitalization for heart failure, Left ventricular ejection fraction and 3 more. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
nicotinamide adenine dinucleotide
03
Conditions
heart failure (HF)myocardial infarction (MI)
Beyond the preview
Go deeper on ChiCTR2200057074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057074.